Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Trends in clinical development for PD-1/PD-L1 inhibitors

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 19, 163-164 (2020)


Updates & Corrections

  • Correction 14 November 2019: The legend for Figure 1 has been corrected to reflect that there are currently 9 marketed PD-1/PD-L1 inhibitors and the legend for Figure 2 has been expanded for clarity.

Supplementary Information

  1. Supplementary figures

Competing Interests

VHL is an unpaid scientific advisor and holds equity in FX Biopharma. The other authors declare no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links